The effect of secukinumab treatment on hematological parameters in ankylosing spondylitis and psoriatic arthritis

Karataş, Ahmet; Gerçek, Aybüke Nisa; Öz, Burak; Gözel, Nevzat; Sagir, R. Piskin; Gür, Mustafa; Koca, Süleyman Serdar

doi:10.5152/eurjrheum.2020.20109

Cited by 6 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 39 ] Gerdes et al [ 40 ] reported that uric acid levels tended to decrease over 52 weeks of treatment with secukinumab in plaque psoriasis patients. However, Karataş et al [ 41 ] found that serum uric acid levels were not significantly different from baseline in 30 patients with ankylosing spondylitis and six patients with psoriatic arthritis treated with secukinumab for 6 months. Our study revealed slightly lower serum uric acid levels in patients treated with secukinumab for 48 weeks compared with baseline values, but the prevalence of hyperuricemia was not significantly different.…”

Section: Discussionmentioning

confidence: 99%

Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis

Zhao

Cai

Zhang

et al. 2022

Chinese Medical Journal

View full text Add to dashboard Cite

Background: Psoriasis is a chronic systemic inflammatory disease, and hyperuricemia is a common comorbidity in patients with psoriasis. However, there are limited reports on the relationship between serum uric acid levels and biological treatment efficacy. The purposes of this study were to compare the differences in serum uric acid levels between patients with psoriasis and healthy controls and analyze the risk of hyperuricemia. Methods: A total of 196 patients with psoriasis and 191 age- and sex-matched healthy controls were enrolled in this retrospective cohort study. One hundred and twenty-seven patients with severe psoriasis were treated with biologics. Sixty-eight patients received adalimumab, and 59 patients received secukinumab. Serum uric acid levels were measured at baseline, week 24, and week 48 of treatment. Results: Patients with psoriasis had higher serum uric acid levels than healthy controls (6.4 ± 1.7 mg/dL vs. 5.7 ± 1.5 mg/dL, P < 0.001). Hyperuricemia was found in 33.7% (66/196) of patients with psoriasis, which was significantly higher than that in healthy controls (13.1% [25/191], P < 0.001). Serum uric acid levels and hyperuricemia were not related to the severity of psoriasis ( P > 0.05). No significant changes in serum uric acid levels and hyperuricemia were observed following adalimumab treatment ( P > 0.05). The serum uric acid level in patients treated with secukinumab was 6.7 ± 1.6 mg/dL at week 24, which was not statistically different from that at baseline (6.6 ± 1.4 mg/dL, P = 0.885). Serum uric acid levels were significantly decreased at week 48 (6.3 ± 1.5 mg/dL vs. 6.6 ± 1.4 mg/dL, P = 0.007) in patients treated with secukinumab. Secukinumab had no significant effect on hyperuricemia either ( P > 0.05). Conclusions: The serum uric acid levels and prevalence of hyperuricemia in patients with psoriasis were significantly higher than those in healthy controls. Secukinumab treatment for 48 weeks successfully decreased serum uric acid levels in patients with psoriasis, whereas adalimumab had no significant effect on serum uric acid levels.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis

Zhao

Cai

Zhang

et al. 2022

Chinese Medical Journal

View full text Add to dashboard Cite

show abstract

“…Unlike these reports, Karataş et al (89) did not find significant differences in SUA levels after 6 months of followup in a small population of 36 patients (30 diagnosed with ankylosing spondylitis and 6 with PsA) receiving treatment with secukinumab.…”

Section: Effects Of Anti-rheumatic Drugs On Serum Uric Acid Levels In Psoriatic Arthritismentioning

confidence: 72%

Hyperuricemia in Psoriatic Arthritis: Epidemiology, Pathophysiology, and Clinical Implications

et al. 2021

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) represents the articular component of the systemic psoriatic disease and the extra-cutaneous disorder most frequently found in patients with psoriasis. Besides the articular involvement, PsA is associated with several metabolic abnormalities such as insulin resistance, hypertension, diabetes and hyperuricemia. Uric acid is the final product of purine metabolism and the etiological substrate of gout. Accumulating evidence highlights the emerging role of hyperuricemia as a major cardiovascular risk factor. Moreover, different studies evaluated the interplay between hyperuricemia and psoriatic disease, suggesting that individuals affected by psoriasis or PsA might present higher serum levels of uric acid and that hyperuricemia might affect severity of clinical manifestations and degree of inflammation in PsA patients. In this review, we focus on the bidirectional relationship between uric acid and PsA, analyzing how uric acid may be involved in the pathogenesis of psoriasis/PsA and how clinical manifestations of PsA and inflammatory mediators are affected by uric acid concentrations. Finally, the effects of anti-rheumatic drugs on uric acid levels and the potential benefit of urate-lowering therapies on psoriasis and PsA were summarized.

show abstract

“…On comparing the effect of each biologic drug on the hematological parameters and indices, it showed no significant difference between different types of biologics in AS patients, while in PSA patients there was a significant difference in the WBCs count which showed significant increase in Secukinumab group than Adalimumab-atto and Golimumab groups, this was explained by Karataş A et al 2022 [ 20 ] who concluded that no negative effects on hematological parameters were observed in patients with AS and PSA who received Secukinumab therapy. While the RDW/platelets ratio and platelets/lymphocytes ratio showed higher levels in Adalimumab-atto and Golimumab groups, respectively, than Secukinumab group.…”

Section: Discussionmentioning

confidence: 97%

Impact of biological and non-biological treatment on hematological indices in patients with ankylosing spondylitis and psoriatic arthritis

Aboud

Galal

Elwafa

et al. 2023

Egypt Rheumatol Rehabil

View full text Add to dashboard Cite

Background Blood dyscrasias are common in patients with rheumatic diseases, as bone marrow and blood cells can be targets for autoimmune processes. This in addition to the potentially adverse effect of the disease-modifying anti-rheumatic drugs used for the treatment of inflammatory arthritis as in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) on blood counts. Aim of this study The aim of this study is to analyze the effect of biologic therapy on complete blood cell parameters, derived ratios, and cell volume indices in Egyptian patients with ankylosing spondylitis and psoriatic arthritis. Results One hundred and twenty Egyptian patients had been included, 60 have ankylosing spondylitis (AS) and 60 have psoriatic arthritis (PSA). On comparing the blood indices between the biologics and non-biologics groups of PSA patients, there was a statistically highly significant reduction in red cell distribution width (RDW%) at the biologics group than non-biologics (p < 0.006), where there was a statistically highly significant increase in Hb (hemoglobin)/RDW ratio and Hb/platelets ratio at the biologics group than non-biologics (p < 0.005). Conclusion As a result, biologic drugs used in rheumatology practice may have some effects on hematological parameters. In our study, no major negative effects on hematological parameters were observed in patients with AS and PsA who received Secukinumab, Adalimumab-atto, or Golimumab biologic therapy. However, the changes in the hematological indices correlates with their potent anti-inflammatory action in rheumatic patients.

show abstract

The effect of secukinumab treatment on hematological parameters in ankylosing spondylitis and psoriatic arthritis

Cited by 6 publications

References 26 publications

Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis

Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis

Hyperuricemia in Psoriatic Arthritis: Epidemiology, Pathophysiology, and Clinical Implications

Impact of biological and non-biological treatment on hematological indices in patients with ankylosing spondylitis and psoriatic arthritis

Contact Info

Product

Resources

About